Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

273 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity.
Gandhi S, Pandey MR, Attwood K, Ji W, Witkiewicz AK, Knudsen ES, Allen C, Tario JD, Wallace PK, Cedeno CD, Levis M, Stack S, Funchain P, Drabick JJ, Bucsek MJ, Puzanov I, Mohammadpour H, Repasky EA, Ernstoff MS. Gandhi S, et al. Among authors: attwood k. Clin Cancer Res. 2021 Jan 1;27(1):87-95. doi: 10.1158/1078-0432.CCR-20-2381. Epub 2020 Oct 30. Clin Cancer Res. 2021. PMID: 33127652 Free PMC article. Clinical Trial.
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating Nintedanib Versus Placebo as Prophylaxis Against Radiation Pneumonitis in Patients With Unresectable NSCLC Undergoing Chemoradiation Therapy.
Dy GK, Prasad D, Kumar P, Attwood K, Adjei AA. Dy GK, et al. Among authors: attwood k. J Thorac Oncol. 2021 Mar;16(3):e19-e20. doi: 10.1016/j.jtho.2020.11.019. J Thorac Oncol. 2021. PMID: 33641724 Free article. Clinical Trial. No abstract available.
Lack of racial differences in clinical outcomes of breast cancer patients receiving neoadjuvant chemotherapy: a single academic center study.
Sarma M, Perimbeti S, Nasir S, Attwood K, Kapoor A, O'Connor T, Early A, Levine EG, Takabe K, Kalinski P, Ambrosone C, Khoury T, Yao S, Gandhi S. Sarma M, et al. Among authors: attwood k. Breast Cancer Res Treat. 2022 Apr;192(2):411-421. doi: 10.1007/s10549-021-06506-y. Epub 2022 Jan 9. Breast Cancer Res Treat. 2022. PMID: 35000093 Free PMC article.
Augmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLC.
Evans R, Lee K, Wallace PK, Reid M, Muhitch J, Dozier A, Mesa C, Luaces PL, Santos-Morales O, Groman A, Cedeno C, Cinquino A, Fisher DT, Puzanov I, Opyrchal M, Fountzilas C, Dai T, Ernstoff M, Attwood K, Hutson A, Johnson C, Mazorra Z, Saavedra D, Leon K, Lage A, Crombet T, Dy GK. Evans R, et al. Among authors: attwood k. Front Oncol. 2022 Aug 3;12:958043. doi: 10.3389/fonc.2022.958043. eCollection 2022. Front Oncol. 2022. PMID: 35992783 Free PMC article.
Predictive and Prognostic Implications of Circulating CX3CR1+ CD8+ T Cells in Non-Small Cell Lung Cancer Patients Treated with Chemo-Immunotherapy.
Abdelfatah E, Long MD, Kajihara R, Oba T, Yamauchi T, Chen H, Sarkar J, Attwood K, Matsuzaki J, Segal BH, Dy GK, Ito F. Abdelfatah E, et al. Among authors: attwood k. Cancer Res Commun. 2023 Mar 30;3(3):510-520. doi: 10.1158/2767-9764.CRC-22-0383. eCollection 2023 Mar. Cancer Res Commun. 2023. PMID: 37009132 Free PMC article.
[No title available]
[No authors listed] [No authors listed] PMID: 38579886
273 results